Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inmune Bio, Inc.INMB · Entity 7094 | Director · Chief Executive Officer | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inmune Bio, Inc.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,294,883 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Exercise / conversion · Acquired 9,014 · Balance 1,294,883 F1: Represents 9,014 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the "April 2024 Warrants"), entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 9,014 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 9,014 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2027-12-31 | Direct | 9,014 |
Reported balance
After 2026-07-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-02 · Other · Disposed 9,014 · Balance 9,014 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 9,014 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the "April 2024 Warrants"), entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 9,014 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 9,014 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2019 Filed Aug 21, 2019 16:34 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 77 | $5.65 | $435.05 |
DisclosureSEC source: 0001213900-19-016455 · ownership.xml · nonDerivative · entry 1 Moss David J · CIK 0001421930 · CFO, Treasurer & Secretary · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,220,494 F1 · shares: The Reporting Person purchased an aggregate of 3,000 shares of the Registrant's common stock on August 20, 2019 in six open market transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.